



Prospects for CNPT

Hikaru Hori^{1,2}

¹*Editor-in-Chief of CNPT*

²*Department of psychiatry, Faculty of medicine, Fukuoka university, Japan*

Received May 25, 2021 / Accepted May 25, 2021 / Published June 18, 2021.

It is a tremendous honor and responsibility to assume the position of Editor-in-Chief of the Clinical neuropsychopharmacology and Therapeutics (CNPT) upon the retirement of Founding Editor-in-Chief, Professor Tsuyoshi Kondo (Ryukyu University) and second Editor-in-Chief, Professor Takeshi Terao (Oita University). Professors Kondo and Terao have provided an exceptional leadership to the journal, and I am grateful to follow in their footsteps.

As Editor-in-Chief, I will seek to build on the foundation laid by Professors Kondo and Terao to publish high-impact, pioneering research in Clinical psychopharmacology. I believe the strength of CNPT is the combination of its clinical focus, which directly affects patient care, and scientific advances with clinical applications.

CNPT is the official journal of the Japanese Society of Clinical Neuropsychopharmacology. CNPT has always focused on clinical psychopharmacology.

CNPT is an international, peer-reviewed, open access (No publication fee) journal publishing on all aspects of neuropsychiatric disorder. The journal welcomes submitted papers covering original research, reviews, meta-analysis, guidelines, expert opinion, letter to the editors, and case reports.

I appreciate that a key function of the Editor-in-Chief is to facilitate the timely review and publication of submitted manuscripts. Improving the time from submission to editorial decision to publication is essential, so our readers can obtain the most up-to-date information as quickly as possible. I try to make the first decision within 2 weeks after submitting.

I believe this is an exciting time in psychopharmacology, and I am enthusiastic to serve as CNPT Editor-in-Chief. I am thankful and appreciative for this opportunity, and I look forward to my new role.